Effects of Low, Moderate, and High Intensity Exercise on Functional Impairment and ADHD Symptoms: A Randomized Pilot Study.

West J Nurs ResJul 12, 2026 (epub)
Clinical ResearchPsychiatry

Meghan E Edmondson, Angela L Ridgel

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of low, moderate, and high intensity exercise on functional impairment and ADHD symptoms in 33 college students. Results indicated significant reductions in functional impairment (F = 7.98, P = .009) and symptom severity (F = 13.43, P = .001), with moderate intensity exercise showing the most consistent benefits across symptoms.

Key findings

  • Functional impairment decreased significantly (F = 7.98, P = .009).
  • Symptom severity showed a significant reduction (F = 13.43, P = .001).
  • Inattentive symptoms improved with low (t = 2.62, P = .015) and moderate intensity exercise (t = 2.61, P = .013).
  • Impulsive symptoms benefited from low (t = 4.06, P = .002) and moderate intensity exercise (t = 1.99, P = .037).

Why it matters

Understanding the impact of exercise intensity on ADHD symptoms in adults can inform treatment strategies. This study suggests that even short-term exercise interventions may lead to significant improvements in functional and symptom outcomes.

Source

PubMed · PMID 42437494

Published in West J Nurs Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.